The DOI matches its Crossref record; 72 of the 74 references it cites were found in a registry or an index.
ApoE Promotes the Proteolytic Degradation of Aβ
Open accessAbstract
Apolipoprotein E is associated with age-related risk for Alzheimer's disease and plays critical roles in Abeta homeostasis. We report that ApoE plays a role in facilitating the proteolytic clearance of soluble Abeta from the brain. The endolytic degradation of Abeta peptides within microglia by neprilysin and related enzymes is dramatically enhanced by ApoE. Similarly, Abeta degradation extracellularly by insulin-degrading enzyme is facilitated by ApoE. The capacity of ApoE to promote Abeta degradation is dependent upon the ApoE isoform and its lipidation status. The enhanced expression of lipidated ApoE, through the activation of liver X receptors, stimulates Abeta degradation. Indeed, aged Tg2576 mice treated with the LXR agonist GW3965 exhibited a dramatic reduction in brain Abeta load. GW3965 treatment also reversed contextual memory deficits. These data demonstrate a mechanism through which ApoE facilitates the clearance of Abeta from the brain and suggest that LXR agonists may represent a novel therapy for AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“APOE3 promotes enzyme-mediated degradation of A 𝛃 in microglia more efficiently than APOE4 (295), suggesting the APOE and microglia play a role in the innate immune response in AD (368).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [295]
In the citing paper
“In this regard, ApoE is indeed tightly connected to the turnover of Ab 1 -42 , since it plays a critical role in the normal proteolytic clearance of Ab 1 -42 (14).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [14]
In the citing paper
“One recent in vitro study found that human apoE isoforms differed in their ability to facilitate neprilysin-mediated degradation of Aβ42 within microglia, with apoE4 being the least effective in facilitating Aβ degradation compared to apoE2 or apoE3 (60).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [60]
In the citing paper
“Several studies demonstrated that apoE isoforms can differentially affect Aβ clearance (Deane et al., 2008; Jiang et al., 2008; Castellano et al., 2011).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“In addition, several studies have shown that activation of Lxr increases mouse apoE and decreases Aβ levels (Jiang et al., 2008).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“LXR agonist treatment alleviates AD-like pathology in mouse models of amyloidosis, possibly by inducing Abca1 expression (29, 43–48).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [29]
In the citing paper
“In addition to its role in A secretion, ABCA1 has been also shown to decrease A levels by promoting extracellular A clearance in both neurons and glial cells (Jiang et al., 2008;Kim et al., 2012).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Jiang et al., 2008
In the citing paper
“A previous report demonstrated that extracellular A degradation by proteases, such as insulin-degrading enzyme, is influenced by the lipidation status of ApoE (Jiang et al., 2008).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Jiang et al., 2008
In the citing paper
“ApoE lipidation by ABCA1 is critical for A clearance (Jiang et al., 2008;Kim et al., 2012).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Jiang et al., 2008
In the citing paper
“we and others have shown that ABCA1 is required for the effective clearance of A by neuronal and glial cells”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Jiang et al., 2008
In the citing paper
“A recent in vitro study demonstrated that the presence of fully lipidated apoE is required for effective degradation of Aβ in microglia (Jiang et al., 2008; Terwel et al., 2011).”
From miR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression (2012) · cites this paper as Jiang et al., 2008
In the citing paper
“More recent studies in transgenic mouse models of AD have shown that microglia migrate to amyloid plaques and may alter plaque growth dynamics (9–12).”
From Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice (2013) · cites this paper as [10]
In the citing paper
“ABCA1-mediated lipidation of apoE may play a key role in facilitating Aβ degradation by Aβ-degrading enzymes (Jiang et al., 2008).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Jiang et al., 2008
In the citing paper
“In addition, treatment of several AD Tg mice models with liver X receptor or retinoid X receptor agonists, which upregulate ApoE expression and enhance its lipidation status, resulted in reduction of Ab plaque load through enhancing clearance of Ab by glial cells.43,44”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [43]
In the citing paper
“These published data indicate that the ApoE/Ab interaction may result in multidirectional effects that may promote Ab degradation by nonneuronal cells 43,44 while enhancing Ab accumulation in neurons.”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [43]
In the citing paper
“Short-term administration of LXR agonists TO901317 and GW3965 to 5-month-old preplaque Tg2576 mice improved fear conditioning (Riddell et al., 2007;Jiang et al., 2008)”
From Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-α Expression for Microglial Aβ Phagocytosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“Long-term treatment with GW3965 has been shown to reduce plaque formation by 50% in aged Tg2576 mice (Jiang et al., 2008).”
From Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-α Expression for Microglial Aβ Phagocytosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“Previously, it has been observed that the LXR agonist GW3965 stimulates degradation of soluble A in astroglial and microglial cultures dependent on ApoE and its lipidation status (Jiang et al., 2008).”
From Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-α Expression for Microglial Aβ Phagocytosis (2011) · cites this paper as Jiang et al., 2008
In the citing paper
“Importantly, apoE-containing HDL particles facilitate the proteolytic degradation of soluble Aβ (sAβ) (Jiang et al., 2008).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Jiang et al., 2008
In the citing paper
“We report that astrocytes have the capacity to take up sAβ and degrade it in an apoE-dependent manner, similar to microglia (Figs. 1, 2; Jiang et al., 2008).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Jiang et al., 2008
In the citing paper
“We have previously documented that apoE acts to facilitate the proteolysis of soluble Aβ peptides both in the interstitial fluid and intracellularly by microglia through the actions of IDE and neprilysin, respectively (Jiang et al., 2008).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Jiang et al., 2008
In the citing paper
“Lipidated ApoE has anti-inflammatory effects and promotes Aβ metabolism (12)”
From Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes (2024) · cites this paper as [12]
In the citing paper
“the administration of RXR or LXR agonists reduces Aβ aggregation and restores cognitive function in AD mouse model (11, 12)”
From Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes (2024) · cites this paper as [12]
In the citing paper
“Lipidated ApoE has anti-inflammatory effects and promotes Aβ metabolism (12)”
From Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes (2024) · cites this paper as [12]
In the citing paper
“Two in vitro studies have also demonstrated that apoE can facilitate the cellular degradation of Aβ (Jiang et al., 2008; Koistinaho et al., 2004).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Jiang et al., 2008
In the citing paper
“suggesting that ABCA1 affects Aβ clearance via apoE (Jiang et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Jiang et al., 2008
In the citing paper
“A recent in vitro study demonstrated that the presence of fully lipidated apoE was necessary for effective degradation of Aβ in microglia, suggesting that ABCA1 affects Aβ clearance via apoE (Jiang et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Jiang et al., 2008
In the citing paper
“One common hypothesis states that APOE sequesters soluble Aβ in the extracellular space resulting in cellular uptake and catabolism of this neurotoxic peptide. This hypothesis is supported by many in vitro studies (Koistinaho et al., 2004; Morikawa et al., 2005; Jiang et al., 2008).”
From The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain (2013) · cites this paper as Jiang et al., 2008
In the citing paper
“In the brain, endocytic pathways in glia cells (likely the LDL receptor) and in neurons are implicated in cellular catabolism of APOE/Aβ complexes (Koistinaho et al., 2004; Jiang et al., 2008; Holtzman et al., 2012).”
From The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain (2013) · cites this paper as Jiang et al., 2008
In the citing paper
“ApoE4 cells are less efficient in promoting intracellular A42 degradation compared with ApoE3 cells (Jiang et al., 2008).”
From ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes (2019) · cites this paper as Jiang et al., 2008
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,526
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 2×
“, 1995) and exhibit extensive deposits of Aβ by one year of age (Kawarabayashi et al., 2001).”
BackgroundMetabolic Regulation of Brain Aβ by Neprilysin
Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C. J., Hama, E., Lee, H.-J., & Saido, T. C. (2001) · Science · doi:10.1126/science.1059946 · Cited by 982
Liver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978
Self-citationIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Flagged first, then by citations
2 of the 74 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 875
Tow, W., Chee, P. Y., Sundralingam, U., & Palanisamy, U. D. (2022) · Nutrients · doi:10.3390/nu14173494 · Cited by 42
Host and Viral Factors Influencing the Pathogenesis of HIV-Associated Neurocognitive Disorders
Jayadev, S., & Garden, G. A. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9154-6 · Cited by 37
Abyadeh, M., Djafarian, K., Heydarinejad, F., Alizadeh, S., & Shab‐Bidar, S. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01381-1 · Cited by 37
Alzheimer’s Disease: A Contextual Link with Nitric Oxide Synthase
Dubey, H., Gulati, K., & Ray, A. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666191129103117 · Cited by 41
The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease
Chernick, D., Zhong, R., & Li, L. (2020) · Biomolecules · doi:10.3390/biom10091276 · Cited by 39
Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β
Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 41
Endothelin-converting enzyme-1 in Alzheimer's disease and vascular dementia
Palmer, J. C., Kehoe, P. G., & Love, S. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01084.x · Cited by 38
Genetics and epigenetics of Alzheimer's disease
Alagiakrishnan, K., Gill, S. S., & Fagarasanu, A. D. (2012) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2011-130363 · Cited by 40
Fitz, N. F., Tapias, V., Cronican, A. A., Castranio, E. L., Saleem, M., Carter, A. Y., Lefterova, M. I., Lefterov, I. M., & Koldamova, R. P. (2015) · Brain · doi:10.1093/brain/awv293 · Cited by 38
The Continuing Failure of Bexarotene in Alzheimer’s Disease Mice
Balducci, C., Paladini, A., Micotti, E., Tolomeo, D., Vitola, P. L., Grigoli, E., Richardson, J. C., & Forloni, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150029 · Cited by 37
Self-citationInfliximab ameliorates AD-associated object recognition memory impairment
Kim, D. H., Choi, S., Jho, J., Park, M., Kang, J., Park, S. J., Ryu, J. H., Jo, J., Kim, H. H., & Kim, B. C. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.001 · Cited by 37
Ding, X., Kryscio, R. J., Turner, J., Jicha, G. A., Cooper, G. E., Caban‐Holt, A., Schmitt, F. A., & Abner, E. L. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14393 · Cited by 37
Modelling Sporadic Alzheimer’s Disease Using Induced Pluripotent Stem Cells
Rowland, H. A., Hooper, N. M., & Kellett, K. A. B. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2663-z · Cited by 38
Muñoz-Cabrera, J. M., Sandoval-Hernández, A. G., Niño, A., Báez, T., Bustos-Rangel, A., Cardona‐Gómez, G. P., Múnera, A., & Arboleda, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223578 · Cited by 39
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
Castaño, D., Rattanasopa, C., Monteiro-Cardoso, V. F., Corlianò, M., Liu, Y., Zhong, A., Rusu, M., Liehn, E. A., & Singaraja, R. R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.013 · Cited by 37
Sodhi, R. K., Singh, N., & Jaggi, A. S. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0654-6 · Cited by 36
Klein, C., Mathis, C., Leva, G., Patte‐Mensah, C., Cassel, J., Maître, M., & Mensah‐Nyagan, A. G. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.003 · Cited by 36
Yang, Y. J., Cudaback, E., Jorstad, N. L., Hemingway, J. F., Hagan, C. E., Melief, E. J., Li, X., Yoo, T., Khademi, S. B., Montine, K. S., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.009 · Cited by 37
RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment
Lefterov, I. M., Schug, J., Mounier, A., Nam, K. N., Fitz, N. F., & Koldamova, R. P. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.05.019 · Cited by 36
Proton pump inhibitor Lansoprazole is a nuclear liver X receptor agonist
Cronican, A. A., Fitz, N. F., Pham, T., Fogg, A., Kifer, B., Koldamova, R. P., & Lefterov, I. M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.018 · Cited by 36
Nam, K. N., Mounier, A., Fitz, N. F., Wolfe, C. M., Schug, J., Lefterov, I. M., & Koldamova, R. P. (2016) · Scientific Reports · doi:10.1038/srep24048 · Cited by 36
Extracellular Proteolysis of Apolipoprotein E (apoE) by Secreted Serine Neuronal Protease
Tamboli, I. Y., Heo, D., & Rebeck, G. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093120 · Cited by 35
The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer’s Disease
Ehtezazi, T., Rahman, K., Davies, R., & Leach, A. G. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220071 · Cited by 37
Liu, Z., Zhu, H., Fang, G., Walsh, K. R., Mwamburi, M., Wolozin, B. L., Abdul‐Hay, S. O., Ikezu, T., Leissring, M. A., & Qiu, W. Q. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111472 · Cited by 35
The Interplay Between Apolipoprotein E4 and the Autophagic–Endocytic–Lysosomal Axis
Schmukler, E., Michaelson, D. M., & Pinkas-Kramarski, R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0892-4 · Cited by 35
24(S)-Saringosterol Prevents Cognitive Decline in a Mouse Model for Alzheimer’s Disease
Martens, N., Schepers, M., Zhan, N., Leijten, F. P. J., Voortman, G. J., Tiane, A., Rombaut, B., Poisquet, J., van de Sande, N., Kerksiek, A., et al. (2021) · Marine Drugs · doi:10.3390/md19040190 · Cited by 37
IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENT
Villeneuve, S., & Jagust, W. J. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.47 · Cited by 32
Fitz, N. F., Castranio, E. L., Carter, A. Y., Kodali, R. B., Lefterov, I. M., & Koldamova, R. P. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132789 · Cited by 37
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype
Lane, R. M., & He, Y. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.005 · Cited by 35
ApoE mimetic peptide decreases Aβ production in vitro and in vivo
Minami, S. S., Cordova, A., Cirrito, J. R., Tesoriero, J. A., Babus, L. W., Davis, G. C., Dakshanamurthy, S., Turner, R. S., Pak, D. T., Rebeck, G. W., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-16 · Cited by 34
The prognostic value of amyloid imaging
Gelosa, G., & Brooks, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2108-x · Cited by 35
Huang, L., Liu, X., Cheng, B., & Huang, K. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.01.007 · Cited by 34
Hostage, C. A., Choudhury, K. R., Doraiswamy, P. M., Petrella, J. R., & Initiative, A. D. N. (2014) · Radiology · doi:10.1148/radiol.13131041 · Cited by 34
Burke, S. L., Maramaldi, P., Cadet, T. J., & Kukull, W. A. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4709 · Cited by 35
Stringa, N., van Schoor, N. M., Milaneschi, Y., Ikram, M. A., Panta, V. D., Koolhaas, C. M., Voortman, T., Bandinelli, S., Wolters, F. J., & Huisman, M. A. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa054 · Cited by 35
Apolipoprotein-E forms dimers in human frontal cortex and hippocampus
Elliott, D. A., Halliday, G. M., & Garner, B. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-23 · Cited by 31
Sandoval-Hernández, A. G., Hernández, H. G., Restrepo, A., Muñoz‐Manco, J. I., Bayón, G. F., Fernández, A. F., Fraga, M. F., Cardona‐Gómez, G. P., Arboleda, H., & Arboleda, G. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0665-8 · Cited by 35
Li, C., Guo, X., Lei, M., Wu, J., Jin, J.-Z., Shi, X., Zhu, Z., Rukachaisirikul, V., Hu, L., Wen, T., et al. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.94 · Cited by 33
Relation between plasma and brain lipids
Wellington, C. L., & Frikke-Schmidt, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000291 · Cited by 33
Apolipoprotein E Regulates Injury-Induced Activation of Hippocampal Neural Stem and Progenitor Cells
Hong, S. J., Washington, P. M., Kim, A., Yang, C.-P., Yu, T., & Kernie, S. G. (2015) · Journal of Neurotrauma · doi:10.1089/neu.2014.3860 · Cited by 33
Alzheimer's disease genetics: lessons to improve disease modelling
Guerreiro, R. J., & Hardy, J. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390910 · Cited by 33
Enrichment factors for clinical trials in mild‐to‐moderate Alzheimer's disease
Ballard, C. G., Atri, A., Boneva, N., Cummings, J. L., Frölich, L., Molinuevo, J. L., Tariot, P. N., & Rakêt, L. L. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.04.001 · Cited by 33
de Oliveira, F. F., Chen, E., Smith, M. D. A. C., & Bertolucci, P. H. F. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01588-7 · Cited by 34
Wincewicz, D., & Braszko, J. J. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320314526269 · Cited by 33
Mechanisms of Neural and Behavioral Dysfunction in Alzheimer’s Disease
Wesson, D. W., Nixon, R. A., Levy, E., & Wilson, D. A. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8177-1 · Cited by 34
Human APOE genotype affects intraneuronal A 1-42 accumulation in a lentiviral gene transfer model
Zhao, W., Dumanis, S. B., Tamboli, I. Y., Rodriguez, G. A., Jo LaDu, M., Moussa, C. E. H., & William Rebeck, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt525 · Cited by 32
Báez-Becerra, C. T., Filipello, F., Sandoval-Hernández, A. G., Arboleda, H., & Arboleda, G. (2018) · Neurotoxicity Research · doi:10.1007/s12640-017-9845-3 · Cited by 34
Targeting Insulin for Alzheimer’s Disease: Mechanisms, Status and Potential Directions
Lee, J. H., Jahrling, J. B., Denner, L. A., & Dineley, K. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179923 · Cited by 36
Lane, R. M., & Darreh‐Shori, T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142268 · Cited by 30
Feng, C., Yin, J., Yang, J., & Cao, L. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.12.017 · Cited by 31
Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
Koch, M., Furtado, J. D., Falk, K., Leypoldt, F., Mukamal, K. J., & Jensen, M. K. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.007 · Cited by 31
Casali, B. T., Reed-Geaghan, E. G., & Landreth, G. E. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1091-y · Cited by 30
Self-citationYang, Y., García-Cruzado, M., Zeng, H., Camprubí-Ferrer, L., Bahatyrevich-Kharitonik, B., Bachiller, S., & Deierborg, T. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.07.006 · Cited by 31
Cui, W., Sun, Y., Wang, Z., Xu, C., Xu, L., Wang, F., Chen, Z., Peng, Y., & Li, R. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0513-3 · Cited by 35
Preclinical Success against Alzheimer's Disease with an Old Drug
LaFerla, F. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmcibr1204890 · Cited by 30
Lane, R. M., & He, Y. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.01.050 · Cited by 29
ADNI, Luo, X., Qiu, T., Jia, Y., Huang, P., Xu, X., Yu, X., Shen, Z., Jiaerken, Y., Guan, X., et al. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9600-z · Cited by 30
Khatib, T., Chisholm, D. R., Whiting, A., Platt, B., & McCaffery, P. J. A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190931 · Cited by 31
Retinoic acid receptor-targeted drugs in neurodegenerative disease
Clark, J. N., Whiting, A., & McCaffery, P. J. A. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1811232 · Cited by 35
Zhang, Y., Gao, H., Zheng, W., & Xu, H. J. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105824 · Cited by 31
Aziz, T. A., Nadeem, A. A., Sarwar, A., Perveen, I., Hussain, N., Khan, A. A., Daudzai, Z., Cui, H., & Lin, L. (2023) · Biomedicines · doi:10.3390/biomedicines11020354 · Cited by 31
Alzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets
Paniri, A., Hosseini, M. M., & Akhavan‐Niaki, H. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03626-y · Cited by 34
Perez, F. P., Bose, D., Maloney, B., Nho, K. T., Shah, K., & Lahiri, D. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131544 · Cited by 31
Suon, S., Zhao, J. J., Villarreal, S. A., Anumula, N., Liu, M., Carangia, L. M., Renger, J. J., & Zerbinatti, C. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-44 · Cited by 31
The role of the ATP-Binding Cassette A1 (ABCA1) in neurological disorders: a mechanistic review
Paseban, T., Alavi, M. S., Etemad, L., & Roohbakhsh, A. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2235718 · Cited by 32
Cholesterol Metabolism in Neurodegenerative Diseases
He, K., Zhao, Z., Zhang, J., Li, D., Wang, S., & Liu, Q. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0674 · Cited by 30
Wei, X. L., Herbst, A. J., Ma, D., Aiken, J. M., & Li, L. (2011) · Journal of Proteome Research · doi:10.1021/pr2000495 · Cited by 29
Wang, X., Li, H., Sheng, Y., He, B., Liu, Z., Li, W., Yu, S., Wang, J., Zhang, Y., Chen, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116071 · Cited by 29
Why Alzheimer's Disease Starts with a Memory Impairment: Neurophysiological Insight
Arshavsky, Y. I. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1339 · Cited by 29
Body fluid biomarkers in Alzheimer's disease.
Lu, H., Zhu, X., Jiang, T., Yu, J., & Tan, L. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.02.13 · Cited by 29
Zhuang, J., Zhang, H., Zhou, R., Chen, L., Chen, J., & Shen, X. (2013) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2013.09.002 · Cited by 31
HIV-associated dementia in the era of highly active antiretroviral therapy (HAART)
Xia, C., Luo, D., Yu, X., Jiang, S., & Liu, S. (2011) · Microbes and Infection · doi:10.1016/j.micinf.2011.01.004 · Cited by 29
HIV-1 Reduces Aβ-Degrading Enzymatic Activities in Primary Human Mononuclear Phagocytes
Lan, X., Xu, J., Kiyota, T., Peng, H., Zheng, J., & Ikezu, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100211 · Cited by 29
Gao, C., Wang, Q., Chung, S. K., & Shen, J. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.02.001 · Cited by 28
Jha, N. K., Kar, R., & Niranjan, R. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190412121811 · Cited by 30
A megalin polymorphism associated with promoter activity and Alzheimer's disease risk
Vargas, T., Bullido, M. J., Martı́nez-Garcı́a, A., Antequera, D., Clarimón, J., Rosich-Estragó, M., Martín‐Requero, Á., Mateo, I., Rodríguez‐Rodríguez, E., Cuadrada, E. V., et al. (2010) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31056 · Cited by 29
Global cPILOT analysis of the APP/PS‐1 mouse liver proteome
Evans, A. R., Gu, L., Guerrero, R., & Robinson, R. A. S. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400149 · Cited by 26
Initiative, A. D. N., Luo, X., Jiaerken, Y., Yu, X., Huang, P., Qiu, T., Jia, Y., Sun, J., Zhou, J., & Zhang, M. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9571-0 · Cited by 29
Advances in Modeling Alzheimer's Disease In Vitro
Sharma, N. S., Karan, A., Lee, D.-H., Yan, Z., & Xie, J. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100097 · Cited by 31
Jan, A., Karasinska, J. M., Kang, M. H., de Haan, W., Ruddle, P., Kaur, A., Connolly, C., Leavitt, B. R., Sorensen, P. H., & Hayden, M. R. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.05.007 · Cited by 28
Transporters as Drug Targets in Neurological Diseases
Qosa, H., Mohamed, L., Alqahtani, S., Abuasal, B., Hill, R., & Kaddoumi, A. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.435 · Cited by 31
Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer’s Disease
Johansson, J. U., Woodling, N. S., Shi, J., & Andreasson, K. I. (2015) · Current Immunology Reviews · doi:10.2174/1573395511666150707181414 · Cited by 28
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 32
Liver X Receptor Regulation of Glial Cell Functions in the CNS
Song, X., Wu, W., Warner, M. N., & Gustafsson, J.-Α. (2022) · Biomedicines · doi:10.3390/biomedicines10092165 · Cited by 28
de Frutos‐Lucas, J., Sewell, K. R., García‐Colomo, A., Markovic, S. J., Erickson, K. I., & Brown, B. M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01170-4 · Cited by 26
Lénárt, N., Szegedi, V., Juhász, G., Kasztner, A., Horváth, J., Bereczki, E., Tóth, M. E., Penke, B., & Sántha, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046007 · Cited by 27
Dorey, E., Bamji‐Mirza, M., Najem, D., Li, Y., Liu, H., Callaghan, D., Walker, D. G., Lue, L., Stanimirovic, D. B., & Zhang, W. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160133 · Cited by 28
Unraveling the genes implicated in Alzheimer's disease
Giri, M., Shah, A., Upreti, B., & Rai, J. C. (2017) · Biomedical Reports · doi:10.3892/br.2017.927 · Cited by 25
Apolipoproteins and Alzheimer's pathophysiology
Koch, M., DeKosky, S. T., Fitzpatrick, A. L., Furtado, J. D., López, O. L., Kuller, L. H., Mackey, R. H., Hughes, T. M., Mukamal, K. J., & Jensen, M. K. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.001 · Cited by 26
Lee, L., Chou, W., Chen, W.-P., Wang, M.-F., Chen, Y., Chen, C., & Tung, K. (2021) · Nutrients · doi:10.3390/nu13103659 · Cited by 26
Pahnke, J., Bascuñana, P., Brackhan, M., Stefan, K., Namasivayam, V., Koldamova, R. P., Wu, J., Möhle, L., & Stefan, S. M. (2021) · Free Neuropathology · doi:10.17879/freeneuropathology-2021-3528 · Cited by 29
Defects of Nutrient Signaling and Autophagy in Neurodegeneration
Ondaro, J., Hernández-Eguiazu, H., Garciandia-Arcelus, M., Loera‐Valencia, R., Rodríguez-Gómez, L., Jiménez-Zúñiga, A., Goikolea, J., Rodriguez‐Rodriguez, P., Ruiz‐Martínez, J., Moreno, F., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.836196 · Cited by 28
Natunen, T., Martiskainen, H., Sarajärvi, T., Helisalmi, S., Pursiheimo, J., Viswanathan, J., Laitinen, M. H., Mäkinen, P. M., Kauppinen, T., Rauramaa, T. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080700 · Cited by 26
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 28
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Barreto, G. E., BUNGAU, S. G., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02065-3 · Cited by 27
Maetzler, W., Stoycheva, V., Schmid, B., Schulte, C., Hauser, A., Brockmann, K., Melms, A., Gasser, T., & Berg, D. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101197 · Cited by 25
Aging reduces glial uptake and promotes extracellular accumulation of Aβ from a lentiviral vector
Zhao, W., Zhang, J., Davis, E. G., & Rebeck, G. W. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00210 · Cited by 24
Guo, X., Sun, G., Zhou, T., Xu, X., Zhu, Z., Rukachaisirikul, V., Hu, L., & Shen, X. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.80 · Cited by 25
Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion
Dresselhaus, E., Duerr, J. M., Vincent, F., Sylvain, E. K., Beyna, M., Lanyon, L. F., LaChapelle, E., Pettersson, M., Bales, K. R., & Ramaswamy, G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194661 · Cited by 25
Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases
Loch, R. A., Wang, H., Perálvarez‐Marín, A., Berger, P., Nielsen, H. M., Chroni, A., & Luo, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.022 · Cited by 26
Metadata
- Authors
- Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., Richardson, J. C., Smith, J. D., Comery, T. A., Riddell, D., Holtzman, D. M., Tontonoz, P., & Landreth, G. E.
- Affiliations
- Case Western Reserve University (US)
- Howard Hughes Medical Institute (US)
- Cleveland Clinic (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Wyeth (US)
- Washington University in St. Louis (US)
- Corresponding author
- Landreth, Gary E.
- ORCID
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2008-06
- Volume
- 58
- Issue
- 5
- Pages
- 681-693
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC2493297
- OpenAlex
- W1994554610
- Cited by
- 876
- References
- 74
- Citations by year
- 2026: 15 · 2025: 34 · 2024: 33 · 2023: 37 · 2022: 35 · 2021: 42 · 2020: 42 · 2019: 47 · 2018: 46 · 2017: 50 · 2016: 57 · 2015: 60 · 2014: 70 · 2013: 70 · 2012: 56
- FWCI
- 41.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute on Aging (R01AG013956, R01AG020202, AG020202, R01AG030482, F32AG24031, F32AG024031, R37AG013956, AG13956)
- National Heart, Lung, and Blood Institute (HL3 0568, P01HL030568, R01HL066082, R01HL066088, HL66088)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- apolipoprotein E, amyloid-beta, neprilysin, insulin-degrading enzyme, microglia, APOE isoforms, lipid modification, liver X receptor, GW3965, Tg2576 mice, Alzheimer's disease, memory impairment
- MeSH terms
- Liver X Receptors, Aging, Alzheimer Disease, Animals, Animals, Newborn, Apolipoproteins E, Behavior, Animal, Benzoates, Benzylamines, Brain, Cells, Cultured, Disease Models, Animal, DNA-Binding Proteins, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Memory, Mice, Inbred C57BL, Mice, Transgenic, Peptide Fragments, Time Factors, Amyloid beta-Peptides, Microglia, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, Mice, Orphan Nuclear Receptors, Plaque, Amyloid, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
